BTIG upgraded Aclaris Therapeutics (ACRS) to Buy from Neutral with an $8 price target In a “transformative transaction,” Aclaris has acquired full ex-China rights to an anti-TSLP humanized mAb and anti-TSLP/IL4R bispecific mAb from Chinabased Biosion, the analyst tells investors in a research note. The firm says BSI-045B’s potency is likely best-in-class with 71-times greater potency versus tezepelumab and up to nine-times higher potency versus other anti-TSLP therapies in development. Based on “promising” Phase 2a open label data, BTIG sees potential for BSI-045B to emerge as a possible early-line treatment option for atopic dermatitis.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics upgraded to Overweight from Neutral at Piper Sandler
- Aclaris Therapeutics Expands Pipeline and Strengthens Leadership
- Aclaris Therapeutics enters global license agreement with Biosion
- Aclaris Therapeutics to sell 35.5M shares at $2.25 in private placement
- Aclaris Therapeutics Reports Positive Q3 2024 Milestones